TheY speak about US
Versantis is in Handelszeitung !
Very positive coverage of our team, our lead product, and our first-in-man study currently enrolling patients at Goethe University Clinic Frankfurt.
Versantis is proud to be selected to present at the Investors Summit 2017 as one of the 7 finest startups of Switzerland!
More information and pictures of the event here:
We are proud to announce that Cydan Development, a sponsor of the prestigious MassChallenge accelerator, has awarded one of its five MassChallenge scholarships to Versantis.
The Job Journal introduced Versantis as a model of successful spin-off from ETH Zurich. M Kabbaj and V Forster discuss the challenges and hurdles related to the translation of a pharmaceutical technology from an academic prototype to a marketable product.
We are proud to serve a role model and encourage all entrepreneurs to read the tips we present in the article.
Versantis is a Challenge Finalist of Pioneers Asia.
According to the Pioneers Asia jury, Versantis is addressing a serious problem that has previously been neglected, with a very strong team and expertise.
Nano-antidotes for drug overdose and poisoning
Vincent Forster and Jean-Christophe Leroux
Science Translational Medicine 7(229):p.290ps14
In this perspective article, we critically review the recent progresses in antidotal medicine which are rising to the challenge of the growing overdose epidemic.
In the US, more than 2.5 million people are subjected to drug overdose which is the most common form of deliberate self-harm and accidental death!
The clinical value and potential of Versantis' technology has been endorsed by the prestigious Science Translational Medicine. This is a major achievement for the project and a great recognition from the medical community.
**Read the main article or check our the press coverage below**
We got the kick! Versantis' co-founders gave a solid presentation that satisfied Venture Kick's Jury. We receive the CHF 20'000.- financial support and are now enrolled in the the final stage.
**Have a look at our interview**